


Izencitinib

Chemical Properties

CAS No. :	2051918-33-1
Formula:	C ₂₂ H ₂₆ N ₈
Molecular Weight:	402.50
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn's disease.
Targets(IC50)	JAK
In vitro	Izencitinib (TD-1473), as an effective inhibitor of JAK1, JAK2 and JAK3, can act on the human JAK kinase domain (pKi values are 10.0,8.8 and 9.5, respectively)[1].
In vivo	Izencitinib (TD-1473,1 mg / kg BID) can be used in oxazolone-induced colitis in mice[1].

Solubility Information

Solubility	DMSO: 30 mg/mL (74.53 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.97 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4845 mL	12.4224 mL	24.8447 mL
5 mM	0.4969 mL	2.4845 mL	4.9689 mL
10 mM	0.2484 mL	1.2422 mL	2.4845 mL
50 mM	0.0497 mL	0.2484 mL	0.4969 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kevin S Currie, et al. Small-molecule agents for the treatment of inflammatory bowel disease. *Bioorg Med Chem Lett*. 2019 Aug 15;29(16):2034-2041.

William J Sandborn, et al. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. *J Crohns Colitis*. 2020 Sep 16;14(9):1202-1213.

D. Beattie, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. *Journal of Crohn's and Colitis*, Volume 10, Issue suppl_1, March 2016, Page S123.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481